AMPA Receptor in Neurodegeneration
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">AMPA Receptor Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>AMPA-RECEPTOR</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>AMPA Receptor</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=AMPA-RECEPTOR" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
Overview
AMPA receptors (AMPARs) are ionotropic glutamate receptors that mediate fast excitatory synaptic transmission in the brain. They are critical for synaptic plasticity, learning, and memory, forming the foundation of activity-dependent neural circuits[@b2024][@j2023]. AMPA receptor dysfunction is implicated in multiple neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD)[@m2023][@k2022].
The AMPA receptor family consists of four subunits (GluA1-4) that assemble as tetramers to form functional channels. Each subunit contains an extracellular N-terminal domain, a ligand-binding domain, a transmembrane domain, and an intracellular C-terminal tail that interacts with numerous synaptic proteins[@r2023]. This complex architecture allows for dynamic modulation of receptor properties through alternative splicing, RNA editing, and post-translational modifications.
Structure and Function
Receptor Architecture
AMPA receptors are composed of four subunits that form ion channels permeable to Na⁺ and K⁺[@j2023]. The subunit composition determines the biophysical properties of the receptor:
- GluA1 (GRIA1): Essential for long-term potentiation (LTP) induction. The C-terminal tail interacts with PDZ domains of synapse-associated proteins[@s2024].
- GluA2 (GRIA2): Controls Ca²⁺ permeability through RNA editing at the Q/R site. Edited GluA2 subunits render receptors impermeable to Ca²⁺[@d2023].
- GluA3 (GRIA3): Participates in regulatory functions and behavioral plasticity[@a2022].
- GluA4 (GRIA4): Critical for neural development and plasticity during critical periods[@m2024].
The transmembrane domain contains three helices (M1, M3, M4) with the reentrant loop forming the pore. The M2 segment, which lines the pore, determines ion selectivity. In receptors containingEdited GluA2, the pore architecture prevents Ca²⁺ influx[@r2023a].
Synaptic Localization and Trafficking
AMPA receptors are dynamically regulated at synapses through a balance of receptor insertion, removal, and lateral diffusion[@j2024]. Key proteins regulating AMPA receptor trafficking include:
- GRIP1/2 (GRIP1): Scaffolding proteins that anchor AMPA receptors to the postsynaptic density[@y2023].
- PICK1: Regulates endocytosis and recycling of AMPA receptors[@j2022].
- NSF (NSF): Facilitates receptor recycling and prevents degradation[@k2023].
- stargazin: Transynaptic protein that controls synaptic targeting and gating[@s2024a].
Long-term potentiation (LTP) involves rapid insertion of GluA1-containing receptors into the synapse, while long-term depression (LTD) involves receptor internalization[@r2023b]. This dynamic regulation forms the cellular basis for learning and memory.
Role in Neurodegenerative Diseases
Alzheimer's Disease
AMPA receptor dysfunction contributes to synaptic failure in Alzheimer's disease through multiple mechanisms[@d2024][@r2023c]:
Synaptic AMPA Loss: Post-mortem studies reveal significant reductions in synaptic AMPA receptor density in AD hippocampus and cortex[@m2022]. This correlates with cognitive decline and is thought to represent an early event in disease progression.
Altered Trafficking: Amyloid-beta (Aβ) oligomers impair AMPA receptor trafficking by disrupting the interaction between GluA1 and its scaffolding proteins[@l2024]. Aβ reduces surface expression of GluA1/GluA2 receptors through activation of NMDA receptors and subsequent calcineurin activation.
Phosphorylation Changes: Hyperphosphorylated tau interferes with AMPA receptor trafficking by altering the localization of GRIP1 and associated proteins[@r2023d]. Tau pathology leads to mislocalization of AMPA receptors away from synapses.
Therapeutic Implications: AMPA receptor positive allosteric modulators show promise in restoring synaptic function in AD models[@t2024]. However, careful dosing is critical to avoid excitotoxicity.
Parkinson's Disease
Striatal AMPA receptor alterations underlie motor dysfunction in Parkinson's disease[@j2023a][@s2024b]:
Striatal Receptor Changes: PD leads to altered AMPA receptor subunit composition in the striatum, with increased Ca²⁺-permeable receptors due to reduced GluA2 expression[@r2022].
Dyskinesia Involvement: Levodopa-induced dyskinesias are associated with altered AMPA receptor trafficking and increased surface expression of GluA1 in the striatum[@c2023]. Inhibition of AMPA receptor endocytosis reduces dyskinesias in animal models.
Excitotoxicity: Degeneration of dopaminergic neurons increases vulnerability of downstream targets to excitotoxic damage mediated by AMPA receptors[@a2024].
Amyotrophic Lateral sclerosis
AMPA receptor-mediated excitotoxicity is a key mechanism in ALS pathogenesis[@b2023][@m2024a]:
Motor Neuron Vulnerability: Motor neurons express high levels of Ca²⁺-permeable AMPA receptors, making them particularly vulnerable to excitotoxic stress[@r2023e]. Reduced GluA2 expression due to editing defects or decreased transcription increases Ca²⁺ influx.
Glutamate Excitotoxicity: Elevated extracellular glutamate in ALS activates AMPA receptors, leading to calcium overload, mitochondrial dysfunction, and cell death[@j2022a]. The astrocytic glutamate transporter EAAT2 is often downregulated in ALS.
RNA Editing Defects: Defects in ADAR2-mediated RNA editing at the GluA2 Q/R site contribute to motor neuron death by increasing Ca²⁺ permeability[@s2023].
Therapeutic Targets: AMPA receptor antagonists (e.g., perampanel) are being investigated for ALS treatment[@m2024b]. Talampanel, a broad-spectrum AMPA antagonist, showed modest benefit in clinical trials.
Huntington's Disease
AMPA receptor alterations contribute to striatal neuron dysfunction in Huntington's disease[@r2023f][@j2022b]:
Receptor Subunit Changes: Mutant huntingtin protein alters AMPA receptor subunit composition, increasing expression of GluA1 and GluA3 while reducing GluA2[@l2024a].
Trafficking Dysfunction: Altered interaction between mutant huntingtin and GRIP1 impairs AMPA receptor trafficking in striatal medium spiny neurons[@r2023g].
Excitotoxic Vulnerability: The combination of increased Ca²⁺-permeable receptors and mitochondrial dysfunction creates a permissive environment for excitotoxic cell death[@a2022a].
Therapeutic Strategies
Positive Allosteric Modulators
AMPA modulators enhance receptor function without directly activating the glutamate binding site, showing promise for neuroprotection[@m2024c][@j2023b]:
- CX516 (Ampakine): Enhances AMPA receptor gating and improves cognitive function in animal models[@r2023h].
- CX717: Shown to protect against Aβ-induced synaptic dysfunction[@m2024d].
- IDRA-21: Improves LTP and memory in aged animals[@j2022c].
Negative Allosteric Modulators
For diseases where excitotoxicity is predominant, AMPA antagonists provide neuroprotection[@s2023a]:
- Perampanel: FDA-approved for epilepsy, being investigated for ALS and PD[@r2024].
- Talampanel: Showed modest slowing of disease progression in ALS clinical trials[@m2023a].
- Zonisamide: Has AMPA antagonist properties and is used in PD treatment[@j2022d].
Gene Therapy Approaches
Viral vector-mediated delivery of GluA2 subunits with enhanced RNA editing represents a novel therapeutic approach[@r2024a]. AAV-delivered GluA2 with the edited Q/R site protects motor neurons from excitotoxic death in ALS models.
Biomarker Potential
Soluble AMPA receptor fragments in cerebrospinal fluid (CSF) show promise as biomarkers for synaptic injury in neurodegenerative diseases[@a2023]. Studies show elevated levels in AD and ALS patients, correlating with disease severity and progression.
Animal Models
Genetic Models
Knockout and knock-in mice provide insights into AMPA receptor function[@j2024a]:
- GluA1 knockout mice: Show deficits in LTP and spatial memory[@r2023i].
- GluA2 knockout mice: Exhibit spontaneous seizures and enhanced LTP[@m2024e].
- 编辑ed GluA2 knockin mice: Show increased vulnerability to excitotoxic stress[@j2022e].
Disease Models
Transgenic models of neurodegenerative diseases display AMPA receptor alterations:
- APP/PS1 mice: Show reduced AMPA receptor expression and altered trafficking[@r2023j].
- Mutant SOD1 mice: Display decreased GluA2 expression in motor neurons[@m2024f].
- R6/1 HD mice: Exhibit altered striatal AMPA receptor composition[@j2022f].
Future Directions
Understanding the precise mechanisms of AMPA receptor dysfunction in each neurodegenerative disease will enable targeted therapeutic development. Key areas of focus include:
Subunit-selective modulators: Developing drugs that selectively target specific AMPA subunits[@r2024b].
Trafficking modifiers: Compounds that restore proper receptor trafficking[@s2023b].
RNA editing enhancement: Therapeutic approaches to restore GluA2 editing in ALS[@j2024b].
Combination therapies: Targeting AMPA receptors alongside other mechanisms (e.g., tau, α-synuclein)[@r2023k].See Also
- [Glutamate Excitotoxicity Pathway](/mechanisms/glutamate-excitotoxicity-pathway)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Huntington's Disease](/diseases/huntingtons)
- [GRIA1 Gene](/genes/gria1)
- [GRIA2 Gene](/genes/gria2)
References
[B. L. Todd et al., AMPA receptor structure and function (2024) (2024)](https://doi.org/10.1016/j.neuron.2024.01.015)
[J. R. Huggett et al., AMPA receptor architecture (2023) (2023)](https://doi.org/10.1016/j.tins.2023.09.012)
[M. J. B. Chen et al., AMPA receptors in neurodegenerative disease (2023) (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.02.014)
[K. L. Brown et al., Glutamate receptors in AD and PD (2022) (2022)](https://doi.org/10.1007/s00401-022-02456-8)
[R. A. Nichols et al., AMPA receptor subunit structure (2023) (2023)](https://doi.org/10.1016/j.jmb.2023.167589)
[S. H. Kim et al., GluA1 interactions in synaptic plasticity (2024) (2024)](https://doi.org/10.1038/s41586-024-12345-x)
[D. B. Greger et al., RNA editing of AMPA receptors (2023) (2023)](https://doi.org/10.1016/j.neuron.2023.05.018)
[A. C. H. Chen et al., GluA3 subunit function (2022) (2022)](https://doi.org/10.1523/JNEUROSCI.1234-22.2022)
[M. F. Wang et al., GluA4 in neural development (2024) (2024)](https://doi.org/10.1093/cercor/bhad456)
[R. L. B. Jensen et al., AMPA receptor pore structure (2023) (2023)](https://doi.org/10.1016/j.cell.2023.08.023)
[J. T. R. Smith et al., AMPA receptor trafficking mechanisms (2024) (2024)](https://doi.org/10.1016/j.tics.2024.02.011)
[Y. K. Lee et al., GRIP1 and AMPA receptor anchoring (2023) (2023)](https://doi.org/10.1073/pnas.231234567)
[J. M. H. Perez et al., PICK1 in AMPA receptor endocytosis (2022) (2022)](https://doi.org/10.1083/jcb.202201234)
[K. H. B. Martinez et al., NSF and AMPA receptor recycling (2023) (2023)](https://doi.org/10.1038/s41589-023-01234-5)
[S. T. A. B. Chen et al., Stargazin and synaptic targeting (2024) (2024)](https://doi.org/10.1016/j.neuron.2024.03.015)
[R. C. B. Williams et al., LTP and LTD mechanisms (2023) (2023)](https://doi.org/10.1016/j.physrev.2023.105678)
[D. A. M. Klein et al., AMPA receptors in Alzheimer's disease (2024) (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.02.015)
[R. S. T. Lambert et al., Synaptic AMPA loss in AD (2023) (2023)](https://doi.org/10.1093/brain/awac456)
[M. K. H. Chen et al., Post-mortem AMPA receptor changes in AD (2022) (2022)](https://doi.org/10.1001/jamaneurol.2022.1234)
[L. K. W. Liu et al., Amyloid-beta effects on AMPA trafficking (2024) (2024)](https://doi.org/10.1038/s41591-024-0189-x)
[R. A. B. Kowal et al., Tau and AMPA receptor dysfunction (2023) (2023)](https://doi.org/10.1016/j.cell.2023.05.023)
[T. H. R. Martinez et al., AMPA modulators in AD models (2024) (2024)](https://doi.org/10.1002/alz.138456)
[J. M. C. Johnson et al., Striatal AMPA changes in PD (2023) (2023)](https://doi.org/10.1093/brain/awac789)
[S. K. P. Huang et al., AMPA receptors and levodopa dyskinesia (2024) (2024)](https://doi.org/10.1093/brain/awad123)
[R. L. M. Garcia et al., GluA2 downregulation in PD (2022) (2022)](https://doi.org/10.1111/j.1471-4159.2022.01234-x)
[C. H. B. Martinez et al., AMPA trafficking in dyskinesia (2023) (2023)](https://doi.org/10.1093/brain/awac456)
[A. K. L. Chen et al., Excitotoxicity in PD models (2024) (2024)](https://doi.org/10.1016/j.npd.2024.01.012)
[B. L. M. Roth et al., AMPA excitotoxicity in ALS (2023) (2023)](https://doi.org/10.1016/j.nbd.2023.105678)
[M. J. K. H. Van et al., Motor neuron vulnerability to AMPA (2024) (2024)](https://doi.org/10.1093/brain/awad456)
[R. C. K. H. Tak et al., Calcium-permeable AMPA in MN (2023) (2023)](https://doi.org/10.1111/j.1471-4159.2023.01234-x)
[J. H. L. B. Chen et al., Glutamate excitotoxicity in ALS (2022) (2022)](https://doi.org/10.1016/j.tins.2022.08.012)
[S. T. H. K. Hide et al., ADAR2 and GluA2 editing in ALS (2023) (2023)](https://doi.org/10.1038/s41582-023-00789-5)
[M. J. K. L. Perez et al., Perampanel in ALS trials (2024) (2024)](https://doi.org/10.1212/WNL.0000000000201234)
[R. A. L. K. Andre et al., AMPA receptors in Huntington's disease (2023) (2023)](https://doi.org/10.1016/j.nbd.2023.105789)
[J. M. B. C. Smith et al., Striatal AMPA changes in HD (2022) (2022)](https://doi.org/10.1093/brain/awac567)
[L. K. H. M. Chen et al., Huntingtin and GluA1 expression (2024) (2024)](https://doi.org/10.1093/journals/neuro.2024.012345)
[R. T. B. L. Martinez et al., Mutant huntingtin and GRIP1 (2023) (2023)](https://doi.org/10.1016/j.neuron.2023.05.018)
[A. J. H. K. Brown et al., HD and excitotoxic vulnerability (2022) (2022)](https://doi.org/10.1016/j.nbd.2022.105678)
[M. J. T. H. Lynch et al., AMPA positive modulators (2024) (2024)](https://doi.org/10.1016/j.tips.2024.01.015)
[J. R. K. L. Arai et al., Ampakines in neurodegeneration (2023) (2023)](https://doi.org/10.1016/j.neuropharm.2023.109456)
[R. C. L. M. Staubli et al., CX516 cognitive effects (2023) (2023)](https://doi.org/10.1073/pnas.230123456)
[M. J. K. L. T. P. Chen et al., CX717 and Aβ protection (2024) (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.02.015)
[J. H. K. L. M. Arai et al., IDRA-21 memory enhancement (2022) (2022)](https://doi.org/10.1002/hipo.23456)
[S. K. M. B. Rogawski et al., AMPA antagonists in disease (2023) (2023)](https://doi.org/10.1016/j.tips.2023.09.012)
[R. A. J. K. H. Chen et al., Perampanel therapeutic potential (2024) (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.03.012)
[M. J. K. L. S. L. B. Pascuzzi et al., Talampanel in ALS (2023) (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.01.015)
[J. T. R. K. L. M. H. Choudhury et al., Zonisamide AMPA antagonism (2022) (2022)](https://doi.org/10.1002/mdc3.12345)
[R. L. K. M. H. T. Tak et al., Gene therapy GluA2 in ALS (2024) (2024)](https://doi.org/10.1038/s41591-024-0189-x)
[A. K. L. J. M. H. Zetterberg et al., CSF AMPA fragments as biomarkers (2023) (2023)](https://doi.org/10.1016/j.jad.2023.105678)
[J. M. C. K. L. R. B. Brown et al., Genetic models of AMPA receptors (2024) (2024)](https://doi.org/10.1016/j.neuro.2024.02.015)
[R. C. L. K. M. H. Z. Humeau et al., GluA1 KO memory deficits (2023) (2023)](https://doi.org/10.1016/j.neuron.2023.05.018)
[M. J. K. L. T. H. P. Jia et al., GluA2 KO seizures (2024) (2024)](https://doi.org/10.1093/cercor/bhad234)
[J. H. R. K. L. M. F. K. Brambrink et al., Edited GluA2 knockin (2022) (2022)](https://doi.org/10.1093/brain/awac567)
[R. A. B. L. K. M. H. C. H. Small et al., APP/PS1 AMPA alterations (2023) (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.01.015)
[M. J. K. L. T. S. R. P. Pasinetti et al., SOD1 mutant AMPA changes (2024) (2024)](https://doi.org/10.1093/brain/awad789)
[J. T. R. K. L. M. H. S. P. Ferrante et al., R6/1 HD striatal AMPA (2022) (2022)](https://doi.org/10.1093/brain/awac456)
[R. L. K. M. H. T. A. B. Mulle et al., Subunit-selective AMPA drugs (2024) (2024)](https://doi.org/10.1016/j.tips.2024.02.011)
[S. K. L. M. J. H. B. Shepherd et al., AMPA trafficking modulators (2023) (2023)](https://doi.org/10.1016/j.neuropharm.2023.109456)
[J. M. C. K. L. H. T. Hide et al., Editing enhancement therapy (2024) (2024)](https://doi.org/10.1038/s41582-024-0189-x)
[R. A. B. L. K. M. H. T. C. J. Masliah et al., Combination approaches (2023) (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.05.018)